The oncogene *Evi1*, which codes for a sequence-specific transcription factor, was cloned as a target of activating retroviral insertions in murine myeloid tumors 24 y ago.[@R1] Soon thereafter, its human homolog was found to be transcriptionally activated through rearrangements of chromosome band 3q26,[@R2]^,^[@R3] which are associated with a poor prognosis in acute myeloid leukemia (AML).[@R4] Since then, *EVI1* has emerged repeatedly as retroviral integration site in different organisms, and a role of its overexpression as an indicator of poor prognosis in a variety of hematopoietic malignancies, as well as some solid tumors, has been firmly established. Because of its well-documented clinical importance, understanding the mechanism(s) of action of *EVI1* is of high significance. However, *EVI1* reveals its secrets only slowly, with merely 475 articles containing the search terms "EVI1," "EVI-1" or "MECOM" (the officially assigned, but still rarely used, gene name) deposited in PubMed at the time of writing.

One of the most recent occasions on which *EVI1* gained negative prominence was in the context of a human gene therapy trial for X-linked chronic granulomatous disease (X-CGD).[@R5] Transplantation of gene-modified, autologous hematopoietic stem cells initially provided substantial clinical benefit to two young adults with X-CGD. However, over time, hematopoiesis became dominated by clones with vector integrations into, and transcriptional activation of, the *EVI1* locus. These clones finally evolved into myeloid malignancies, acquiring monosomy 7, a chromosome aberration frequently associated with *EVI1* overexpression in AML, during this process. As a preliminary mechanistic explanation for these findings, experimental expression of *EVI1* in human diploid fibroblasts increased the numbers of cells with aberrant centrosome numbers.[@R5]

In the September 15th issue of *Cell Cycle*, Karakaya and colleagues confirmed and extended these observations.[@R6] Using U2OS osteosarcoma cells inducibly expressing *EVI1* as a model, they show that only 72 h after induction of *EVI1*, 17% of the cells contained centrosome amplifications vs. 5% of the control cells. Analysis of nuclear morphology and time-lapse video microscopy suggested that supernumerary centrosomes resulted from a cytokinesis defect that is known to activate a p53-dependent tetraploidy checkpoint. Indeed, induction of *EVI1* upregulated p53 and siRNA-mediated p53 depletion increased the percentage of polyploid cells after *EVI1* induction. Furthermore, the vast majority of *EVI1*-overexpressing cells with centrosome amplification had low or undetectable levels of the proliferation marker Ki67, indicating that *EVI1*-induced centrosome aberrations were largely confined to cells in G~0~ or early G~1,~ and confirming that *EVI1*-induced tetraploidization caused a cell cycle arrest.[@R6]

These data, together with those from the X-CGD study,[@R5] establish genomic instability as a not previously reported consequence of *EVI1* overexpression, which also might explain its frequent association with monosomy 7. It should be pointed out, though, that chromosome aberrations can also emerge through selection on the background of normal missegregation rates rather than through increased genetic instability.[@R7] In fact, in the Mitelman database,[@R8] in \~39% of AML cases with a 3q26 aberration this was the sole cytogentic anomaly, and for \~82% of 3q26 rearranged cases, only a single clone was reported \[compared with \~43% and \~83%, respectively, for the prognostically favorable t(8;21)(q22;q22)\]. These data do not argue for greatly increased rates of chromosome instability as a consequence of *EVI1* overexpression. However, excessive instability would likely pose the danger of lethal genetic aberrations and thus not be beneficial to a tumor cell, while low-level instability may become apparent from cytogenetic data only through more detailed analyses. In addition to eventual subtle effects on karyotype at the time of diagnosis, modest *EVI1*-induced chromosome instability raises the intriguing possibility that *EVI1* overexpression may cause poor prognosis at least in part by facilitating acquisition of aberrations that allow tumor cells to escape chemotherapy-induced apoptosis. This hypothesis can be tested through quantitative evaluation of chromosome aberrations and clones at diagnosis and relapse (which is caused by cells that survived the initial therapy) in patients with 3q26 rearranged/*EVI1* overexpressing AML and suitable controls. The work of Karakaya et al., in addition to the novel information it provides as it stands, therefore opens new perspectives that may lead to substantial advances in our understanding of how overexpression of *EVI1* contributes to poor prognosis in AML and other malignancies.

Previously published online: [www.landesbioscience.com/journals/cc/article/22392](http://www.landesbioscience.com/journals/cc/article/22392/)

KarakayaKHerbstFBallCGlimmHKrämerALöfflerH Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase Cell Cycle 2012 11 3492 503 10.4161/cc.21801
